Slingshot members are tracking this event:

Celgene (CELG) Presents Phase 2 Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis at AGG Plenary Session

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data A significantly greater proportion of patients with moderate to severe ulcerative colitis achieved clinical remission at 32 weeks with Ozanimod 1 mg versus placebo Clinical response and mucosal healing also significantly improved with Ozanimod 1 mg compared to placebo at week 32 Week 32 safety results consistent with those at week 8
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Ozanimod, Severe Ulcerative Colitis, Touchstone Trial